Tradestie Institutional Equity Comparison Engine
REPL vs EVMN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while REPL counters with relative strength in Momentum & Technical. Fundamentally, REPL trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, REPL sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
REPL N/M vs EVMN N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
REPL
1Y +136.8% vs -61.0% ยท 52W Pos 90% vs 8%
Options & Structure Winner
EVMN
BREAKOUT (23rd %ile IV) vs SURGE (53rd %ile IV)
REPL
NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$21.41
-2.19% 1D
Market Cap
$2.1B
1M Return
+97.15%
1Y Return
+136.84%
Forward P/E
N/M
Unified AI Score
27.4 / 100
SELL
Tech 50.0
Fund 34.0
Flow 67.0
Mom 50.0
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
REPL +136.84%
EVMN -61.03%
Spread: +199.45 pp (REPL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
REPL TTM Op. Margin: 0.0%
EVMN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs EVMN. Trailing 12-month operating profitability (REPL 0.0% vs EVMN 0.0%) and valuation multiples (REPL N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | REPL | EVMN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $315.5M | Larger Scale | REPL |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -115.8% | -69.5% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 90% ($2โ$24) | 8% ($5โ$33) | Stronger Trend | REPL |
| Beta / 30D Volatility Risk Regime | 2.08ฮฒ ยท 100% Vol | 1.05ฮฒ ยท 118% Vol | Lower Realized Risk | REPL |
| Unified Institutional Score Composite Signal | 27.4 / 100 (SELL) | 30.0 / 100 (SELL) | Higher Composite | EVMN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full REPL vs EVMN Buy Guide
REPL
BREAKOUT
98d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither REPL nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.